MAIA Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company focused on developing and commercializing prescription medicines for the U.S. market. The company applies regulatory, clinical, and product development expertise to advance differentiated therapies, often utilizing the FDA’s 505(b)(2) pathway to optimize established active pharmaceutical ingredients and delivery forms.
MAIA collaborates with international and domestic partners to navigate U.S. approval and market entry, targeting opportunities across multiple therapeutic areas. Its work spans formulation development, clinical strategy, and commercialization, aiming to expand patient access to proven treatments through improved dosing, administration, or availability. In the broader chemicals and life sciences value chain, MAIA operates at the interface of pharmaceutical development and market access, translating established molecules into clinically and commercially viable products for the U.S. healthcare system.
MAIA will develop and commercialize Teribone™ in the U.S. to address the growing osteoporosis patient population, expanding access to proven bone-forming therapy.
